EBEwa Balkowiec-Iskra

Ewa Balkowiec-Iskra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ewa Balkowiec-Iskra has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development of treatments for sarcopenia: new challenges, opportunities and perspectives

    by Leo Westbury, Elizabeth M. Curtis, Ewa Balkowiec-Iskra, Antonio Cherubini, Mario Miguel Coelho da Silva Rosa, Paolo Foggi, Yury Kiselev, Andrea Laslop, Sif Ormarsdóttir, Maria Concepcion Prieto Yerro, et al.

    Sarcopenia is characterized by loss of muscle mass, strength and function, and is associated with decline in physical function, falls, fractures and premature mortality. Despite increasing recognition of its clinical and societal burden, progress in translating advances in sarcopenia research into approved pharmacological therapies has remained limited. Potential barriers include heterogeneity in trial design regarding eligibility criteria, follow-up duration and outcomes, as well as limited regulatory harmonization. Given advances in sarcopenia research, the continued absence of approved treatments and the need to integrate perspectives that have emerged since the 2020 ESCEO recommendations for the conduct of sarcopenia clinical trials, this Perspective provides up-to-date expert perspectives on the development of treatments for sarcopenia, informed by discussions held by a working group convened by the World Health Organization Collaborating Centre for Epidemiology of Musculoskeletal Conditions and Ageing. Developments in the definition of sarcopenia, the regulatory landscape and therapeutic approaches are presented, together with considerations for the design of pharmacological trials, including target populations, the selection and assessment of trial outcomes (including digital health measures and patient-reported outcome measures), trial duration, use of biomarkers and patient expectations of treatments.

  • Top Cited Papers
    Open Access

    Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab

    by Lorenzo Guizzaro, Ewa Bałkowiec-Iskra, Marion Haberkamp, Peter G.M. Mol, Alexandre Moreau, Jan Mueller-Berghaus, Daniela Philadelphy, Pavel Balabanov, Juan Garcia, Steffen Thirstrup, et al.


  • Top Cited Papers

    Novel approaches to the stratified management of knee osteoarthritis

    by Nicholas R. Fuggle, Roland Chapurlat, Andrea Laslop, Nasser Al-Daghri, Majed Alokail, Jotheeswaran Amuthavalli Thiyagarajan, Ewa Balkowiec-Iskra, Francis Berenbaum, Angie Botto-Van Bemden, John-Joseph Borg, et al.

    Knee osteoarthritis is a highly prevalent whole-joint disease that is associated with substantial morbidity. If step changes are to be made in the management of knee osteoarthritis, novel patient stratification approaches are needed to identify the most effective treatment for individual patients. Numerous methods for stratifying patients with knee osteoarthritis can be employed; clinical presentation, including co-morbidity and pain phenotype, can influence treatment decisions, and there is a rich history of imaging biomarker use, both from conventional radiographs and, since its development, via MRI, in identifying patients at risk of disease progression, and the latter facilitates the detection of synovitis. The development of novel biochemical biomarkers and the rapid growth of ‘-omics’ technologies provide fresh opportunities to deploy these advances in the stratification of patients with knee osteoarthritis. The health economic landscape in this area is developing, and scoping work has highlighted the need for further studies.


  • Open Access

    Can regulators have a role in facilitating the development of new medicines for Parkinson's disease?

    by Mário Miguel Rosa, Ewa Balkowiec-Iskra

    Parkinson's disease (PD) is the second most frequent neurodegenerative disorder, and its prevalence has doubled in the past 25 years. New formulations of levodopa have recently been marketed that improved the ability to treat PD, but in the European Union, no new active substance for PD has been marketed since 2015, whilst two new agents have been marketed elsewhere. In spite of being the most treatable neurodegenerative disorder, several unmet medical needs still exists in PD, and efforts both from researchers, drug developers and regulators are needed to facilitate further developments in the field. There are several reasons that may account for the lack of new treatments for PD. Regulatory agencies provide scientific advice and have developed several programs to foster drug development. This manuscript discusses the main obstacles identified in the development process, the present status of approvals in European Union and the United States, and the presently available mechanisms to optimize drug development and marketing.


  • Top Cited Papers
    Open Access

    Precision psychiatry roadmap: towards a biology-informed framework for mental disorders

    by Martien J. H. Kas, Brenda W. J. H. Penninx, Gitte M. Knudsen, Bruce Cuthbert, Peter Falkai, Gary S. Sachs, Kerry J. Ressler, Ewa Bałkowiec-Iskra, Florence Butlen-Ducuing, Marion Leboyer, et al.

    The current classification systems for mental disorders provide a uniform symptom-based language to describe and diagnose mental disorders. Clinicians use these classifications to communicate with their patients and colleagues, to treat patients, and when applicable, to request reimbursement from payers. In clinical research and drug development, diagnostic categories are used as enrollment criteria for clinical trials and to inform prescribing information for the appropriate use of therapeutic interventions. However, like other neuropsychiatric diseases, mental disorders arise from the biology of the brain and its bidirectional interaction with the environment. Current classification systems do not reflect this knowledge. With scientific progress in neuroscience, the time has come for global stakeholders to align research efforts to work toward integrating symptomatic, biological, and behavioral information into the definition of mental disorders to advance the development of effective treatments. The European College of Neuropsychopharmacology (ECNP), following the 2024 New Frontiers Meeting, is coordinating a global initiative to design and implement a Precision Psychiatry Roadmap. By mobilizing resources and harmonizing translational methodologies and datasets, the aim is to discuss, design, and implement an iterative framework that incorporates biology-informed evidence into symptom-based syndromes, allowing for more discovery and implementation of mechanism-based effective treatments for mental disorders.


  • Signals from randomized clinical trials predicting hepatotoxicity of flupirtine: systematic review

    by Mahir Fidahic, Emilija Lozo Vukovac, Ewa Balkowiec-Iskra, Darko Krnic, Adriana Andric, Zeljana Margan Koletic, Livia Puljak

    Background The aim of this study was to systematically review clinical trials evaluating the flupirtine to identify any biochemical or clinical indicators that could signal serious hepatotoxicity. Methods This systematic review included randomized controlled trials (RCTs) evaluating flupirtine-containing medicines for any clinical condition. Trials involving any population, comparator, or outcome were considered eligible for inclusion. A comprehensive search was conducted in Embase, MEDLINE, and CENTRAL from their inception until August 14, 2023. The risk of bias (RoB) in the included trials was assessed using Cochrane’s 2011 RoB tool. Due to the heterogeneity of the included trials, a meta-analysis could not be performed. Results A total of 35 trials published between 1983 and 2022 were included in this systematic review, with 1408 participants receiving flupirtine. Only five trials reported any data related to liver function tests. Among these, four trials documented transient, asymptomatic liver abnormalities that returned to normal after the trial period, while one trial was prematurely terminated. One trial reported normal liver test results in all participants. Of the three trials published after 2018, only one acknowledged the withdrawal of flupirtine from the European market. The majority of risk of bias (RoB) domains were classified as having an unclear risk of bias. Conclusion Published RCTs did not report any evidence of serious hepatotoxicity associated with flupirtine based on the available biochemical or clinical data. However, liver function test results were reported in only 5 out of 35 included trials. Published RCTs are not reliable information about flupirtine-related hepatotoxicity. Registration: Protocol was published in PROSPERO (CRD42018085123).

  • Open Access

    Impact of dementia and mild cognitive impairment on bone health in older people

    by Elizabeth M. Curtis, Mario Miguel, Claire McEvoy, Andrea Ticinesi, Carla Torre, Nasser Al-Daghri, Majed Alokail, Ewa Bałkowiec-Iskra, Olivier Bruyère, Nansa Burlet, et al.

    Mild cognitive impairment, dementia and osteoporosis are common diseases of ageing and, with the increasingly ageing global population, are increasing in prevalence. These conditions are closely associated, with shared risk factors, common underlying biological mechanisms and potential direct causal pathways. In this review, the epidemiological and mechanistic links between mild cognitive impairment, dementia and skeletal health are explored. Discussion will focus on how changes in brain and bone signalling can underly associations between these conditions, and will consider the molecular and cellular drivers in the context of inflammation and the gut microbiome. There is a complex interplay between nutritional changes, which may precede or follow the onset of mild cognitive impairment (MCI) or dementia, and bone health. Polypharmacy is common in patients with MCI or dementia, and there are difficult prescribing decisions to be made due to the elevated risk of falls associated with many drugs used for associated problems, which can consequently increase fracture risk. Some medications prescribed for cognitive impairment may directly impact bone health. In addition, patients may have difficulty remembering medication without assistance, meaning that osteoporosis drugs may be prescribed but not taken. Cognitive impairment may be improved or delayed by physical activity and exercise, and there is evidence for the additional benefits of physical activity on falls and fractures. Research gaps and priorities with the aim of reducing the burden of osteoporosis and fractures in people with MCI or dementia will also be discussed.


  • Generating clinical evidence for treatment and prevention options for long COVID

    by Stephanie Buchholz, Eugenia Di Meco, Ewa Z. Bałkowiec-Iskra, Bruno Sepodes, Marco Cavaleri


  • Open Access

    The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers

    by Florence Butlen-Ducuing, Marion Haberkamp, Georgios Aislaitner, Ewa Bałkowiec-Iskra, Taina Mattila, Marika Doucet, Marta Kollb-Sielecka, Pavel Balabanov, Ann-Kristin Leuchs, André Elferink

    According to the World Health Organization (WHO), depressive disorders are currently considered as one of the most disabling medical conditions in the world with one of the highest disability-adjusted life years [1] and this situation has apparently been further worsened during the COVID-19 pandemic [2]. Up to two thirds of patients with major depressive disorders (MDD) do not achieve full remission following an adequate first line standard of care and/or experience residual symptoms such as anxiety, impaired cognition, fatigue, sleep disturbance, or anhedonia [3]. Several attempts are often needed to find the most suitable treatment [4]. Thus, there is a need for medicinal products with better efficacy (e.g., faster onset of action, higher rates of response and remission), improved safety and/or more personalised profiles [5].